Debbie Rigby presents the latest research relevant to pharmacists
A systematic review and meta-analysis of 37 trials involving over 19,000 participants has concluded that hydrolysed formula does not prevent allergic disease in high risk infants. Trials compared the effect on allergic or autoimmune disease or allergic sensitisation with hydrolysed cows’ milk formula to other hydrolysed formula, human breast milk, or a standard cows’ milk formula.
A network meta-analysis of ramdomised trials has concluded there is no role for single-agent paracetamol for the treatment of patients with osteoarthritis irrespective of dose. Diclofenac 150 mg/day was found to be the most effective NSAID available at present, in terms of improving both pain and function. However the safety profile of diclofenac needs to be considered when selecting the preparation and dose for individual patients.
Lancet 2016. Published Online: 17 March 2016
A systematic review and meta-analysis suggests net protection of SGLT2 inhibitors against cardiovascular outcomes and death, largely driven by findings for empagliflozin. SGLT2 inhibitors protected against the risk of major adverse cardiovascular events, cardiovascular death, heart failure and death from any cause. Safety analyses showed consistent increased risks of genital infections.
Lancet Diabetes & Endocrinology. Published Online: 18 March 2016
Canagliflozin, a SGLT2 inhibitor, is associated with an increased incidence of serious adverse events of diabetic ketoacidosis (DKA) in patients with type 1 diabetes inadequately controlled with insulin. Among the 12 patients included in this RCT (n=351) with a serious AE of DKA, blood glucose levels ranged from 9.4 to >44.4 mmol/L.
Diabetes Care March 17, 2016